TheraCryf PLCLSE: TCF

TheraCryf: Ethics submission for Ox-1 Phase 1 study

· Issued by TheraCryf PLC via RNS

Summary by 6ix AI

TheraCryf plc, which develops medicines for addiction and other neuropsychiatric disorders, applied in November 2026 to the Bellberry Human Research Ethics Committee in Australia for approval of a first-in-human Phase 1 study of its lead orexin-1 (Ox-1) receptor antagonist, a drug designed to block the orexin-1 receptor.

Key details

  • The application was made on behalf of its wholly owned subsidiary, TheraCryf Australia Pty Ltd, in line with the November 2026 timetable the company had previously announced.
  • The submission follows completion of the preclinical (pre-human) data package announced on October 19, 2026, including final reporting of 28-day regulatory toxicology studies in two species.

What’s still pending

  • The study needs approval from the Bellberry Human Research Ethics Committee, which the company anticipates but has not yet received.
  • After that approval, the company will lodge a Clinical Trial Notification with Australia's Therapeutic Goods Administration, the national medicines regulator.
  • The company continues to target the necessary approvals by the turn of the year from 2026 into 2027.

6ix AI wrote this summary from the release below and checked it against the release.

Theracryf PLC
18 November 2026

A black background with blue letters

Description automatically generated

18 November 2026

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Ethics submission for Ox-1 Phase 1 study

TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders such as fatigue, announces that it has submitted an application to the Bellberry Human Research Ethics Committee ("HREC") in Australia for a first-in-human Phase 1 study of its lead orexin-1 (Ox-1) receptor antagonist.

The application was submitted on behalf of the Company’s wholly owned subsidiary, TheraCryf Australia Pty Ltd, in line with the November 2026 timetable previously announced. The submission follows completion of the preclinical data package announced on 19 October 2026, including the final reporting of the 28-day regulatory toxicology studies in two species.

Following anticipated HREC approval, the Company will lodge a Clinical Trial Notification (CTN) with Australia’s Therapeutic Goods Administration (TGA). The Company continues to target the necessary approvals by the turn of this calendar year.

Australia provides an efficient and well-established pathway for early-stage clinical studies, which was a key factor in the Company's decision to conduct its Phase 1 programme there.

Dr Huw Jones, Chief Executive Officer of TheraCryf, commented:

“Today’s submission to the ethics committee in Australia is the culmination of a huge body of work by our internal team together with our expert consultants and research partners. It was made exactly in line with our guidance on timing. Securing the approvals to progress to human volunteers, which we anticipate around the turn of this year, would be a major inflection point for our addiction programme and pave the way for us to become a clinical-stage neuropsychiatry company.

“Congratulations to our extended team for delivering yet again. We eagerly anticipate the approval from the Australian authorities and the potential this has to enhance the value of both the programme and the company.

-Ends-

Enquiries

TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, COO

+44 (0)1625 315 090

enquiries@theracryf.com

Strand Hanson (Financial & Nominated Adviser)
James Harris / Carl Holmes / Imogen Ellis / Harry Hiley

+44 (0)20 7409 3494

Turner Pope Investments (Broker)

Andy Thacker / Guy McDougall

+44 (0)20 3657 0050

Northstar Communications (Investor Relations)

Sarah Hollins

+44 (0)113 730 3896

sarah@northstarcommunications.co.uk

About TheraCryf

TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need.

The Group’s lead programme is a novel, potentially best-in-class orexin-1 (Ox-1) receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.

Following completion of its preclinical development package, an application to conduct a first-in-human Phase 1 study of Ox-1 in Australia was submitted for ethics review in November 2026.

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.

The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.

TheraCryf’s headquarters and registered office are at Alderley Park, Cheshire.

For further information, visit: https://theracryf.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TheraCryf PLC on 6ix

Earlier from TheraCryf

All TheraCryf news releases